MediciNova, Inc., a publicly-traded biopharmaceutical company working on developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that it is in late-stage discussions with researchers at Penn State University (lead researcher Dr. Rebecca Bascom) to begin a Phase 2 clinical trial of MN-001 (tipelukast) for…
A protein expressed solely by cells lining the airways is at the center of an interesting new strategy that may help fight pulmonary fibrosis. The protein, secretoglobin (SCGB) 3A2, was investigated during a recent study conducted by the Laboratory of Metabolism at the National Cancer Institutes in the National Institutes of…
The Medical University of South Carolina (MUSC) and Bristol-Myers Squibb Company have announced their joint entry into a translational research collaboration focused on fibrotic diseases, including scleroderma, renal fibrosis and idiopathic pulmonary fibrosis (IPF). Under the agreement, studies designed to improve the mechanistic understanding of fibrosis, explore patient…
Boehringer Ingelheim recently announced that it welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis – An Update of the 2011 Guideline, as it suggests the use of OFEV (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF). This recommendation directed to clinicians is considered…
The lung is constantly subjected to harmful exposures, such as inhaled toxic substances, particulate matter, autoimmune reactions, and viral or bacterial infections that cause injury to the airway and alveolar epithelium cells. In regenerative processes, these injured cells must be replaced as soon as possible. In a recent study published…
Researchers at University of Alabama at Birmingham (UAB) recently published in the Journal of Thoracic Disease, a review article on the role played by specific mesothelial cells in the pleura (the membranes surrounding the lungs) in the development of lung disorders like idiopathic pulmonary fibrosis (IPF). The…
Researchers at the Spanish National Cancer Centre (CNIO) and the Complutense University of Madrid in Spain discovered that telomere damage is a cause of idiopathic pulmonary fibrosis (IPF) development. The study was recently published in the journal Cell Reports and is entitled “…
Dr. Dinesh Khanna from the University of Michigan Health System recently presented at the European League Against Rheumatism (EULAR) 2015 Annual European Congress of Rheumatology in Rome new positive safety data regarding ESBRIET for the treatment of interstitial lung disease (ILD). ILD is a group of disorders that cause progressive…
A new study recently published in the journal PLoS One reported data on a specific imaging tool to assess disease progression in patients with idiopathic pulmonary fibrosis (IPF). The study was conducted by an international research team and is entitled “Visual vs Fully Automatic…
In a new study entitled “Ultrasound signs of pulmonary fibrosis in systemic sclerosis as timely indicators for chest computed tomography,” authors show thoracic ultrasound allows clinical staff to identify early signs of pulmonary fibrosis in systemic sclerosis patients who fail to exhibit symptoms. The study was published…
Get regular updates to your inbox.
